![]() ![]() ![]() If the FDA authorizes emergency use of the kid-sized doses, there’s another hurdle before vaccinations in this age group can begin. An independent expert panel will publicly debate the evidence on Oct. ![]() Now the FDA will have to decide if that evidence is strong enough to expand use to youngsters. “I think we really hit the sweet spot,” said Gruber, who’s also a pediatrician. The kid dosage also proved safe, with similar or fewer temporary side effects - such as sore arms, fever or achiness - that teens experience, he said. Bill Gruber, a Pfizer senior vice president, told The Associated Press. Yet after their second dose, children ages 5 to 11 developed coronavirus-fighting antibody levels just as strong as teenagers and young adults getting the regular-strength shots, Dr. Last month, the companies announced topline results of trial data that found the vaccine to be safe, while prompting a "well tolerated" and "robust" antibody response among the younger, targeted group.įor elementary school-aged kids, Pfizer tested a much lower dose - a third of the amount that’s in each shot given now. The announcement comes one week after the companies submitted to the federal agency initial trial data for that age group. WCSU Goes Virtual For a Week Starting Monday Amid COVID-19 Surge Across State ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |